All Eyes Needed: (Nasdaq: SXTP) Makes Approx 156% Move On Breaking News

*Sponsored by 60 Degrees Pharmaceuticals, Inc. Krypton Street’s Next Potential Breakout Idea is… 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP)  Keep Reading To See Why (SXTP) Is #1 On Our Watchlist This Morning… There’s only around 1.5M shares in the float, setting the stage for significant swing potential if demand begins to shift. The CEO was recently purchasing shares, highlighting strong belief in the company’s future and growth prospects. A $3.40 analyst target suggests a 165% upside from  yesterday’s $1.28 open on January 7, 2025.  An approximate 254% move in just six weeks could signal a  growing public interest. Over 40 patents, including three Orange Book-listed patents, provide market exclusivity and innovation strength. ARAKODA®, addressing a $50–$70M U.S. malaria market, is FDA-approved and commercially available. Pivotal trials for tick-borne diseases and chronic illnesses position the company in key emerging markets. Consider adding (SXTP) to your radar before this morning’s opening bell… January 8, 2025 Dear Reader, When a biotech moves approximately 156% in the pre-market, from $1.405 to $3.60 according to Nasdaq, it’s time to pay attention—and 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) is flexing its muscles with that kind of potential today. 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) announced the enrollment of the first patient in an expanded access clinical study (NCT06478641) to evaluate the efficacy of tafenoquine for treating persistent babesiosis in high-risk patients who have failed standard-of-care treatments. This announcement coincides with (SXTP)’s approximate 156% move in the pre-market to $3.60 according the Nasdaq, surpassing all key moving averages tracked by Barchart, including: 5-day (1.3260) 20-day (1.4360) 50-day (1.1469) 100-day (1.2278) 200-day (2.0483) Case studies published in Clinical Infectious Diseases demonstrated an 80% cure rate for tafenoquine in high-risk, relapsing babesiosis patients. With babesiosis cases rising in the Northeast U.S., the potential cumulative market for ARAKODA® (tafenoquine) exceeds 400K patients by the end of its U.S. patent protection in 2035. CEO Geoff Dow, PhD, highlighted tafenoquine’s potential to provide hope for patients with limited treatment options, emphasizing the importance of this expanded access study in addressing this life-threatening disease.  Keep reading to get up to speed if you missed my email from earlier today. As promised, we’re ready to reveal the name of our next potential breakout idea. Say hello to 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP)—a standout in one of our favorite sectors that’s got several potential catalysts we look for: Ultra-low float of fewer than 2M shares, could set the stage for significant move potential. Momentum Potential with an approximate 254% move in just six weeks, hinting the public is starting to catch on. An analyst target suggesting 165%+ upside, making this a player with growth potential. Triggering 15 Bullish Signals on TradingView’s technical analysis tool, including the Momentum Indicator, using the 15 minute time-frame.   Let’s not overlook their robust intellectual property portfolio, which strengthens their long-term potential. And Benzinga reports recent insider buying, which could signal strong confidence from within. Building on its achievements in malaria prevention, 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) is now advancing efforts to tackle babesiosis, a tick-borne disease that is becoming increasingly prevalent in the U.S.  The company has initiated pivotal trials for acute babesiosis and is preparing to address chronic cases in the near future. With FDA orphan status granted to tafenoquine, the treatment shows promise as a leading option in a space where current therapies fall short.  Babesiosis poses both a critical public health challenge and a substantial market potential, with up to 1 Mln chronic cases in the U.S. and rising acute incidence rates. By targeting this underserved area, 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) is strategically positioning itself to potentially reach over 2 Mln patients. FDA-Approved ARAKODA®: A Game-Changer in Malaria Prevention with a $50–$70M U.S. Market Foothold ARAKODA® (tafenoquine), 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP)’s flagship product, is a revolutionary antimalarial therapy that earned FDA approval in 2018 and became commercially available the following year.  Unlike other treatments, ARAKODA® provides complete protection against all stages of malaria with a convenient weekly dosing schedule—no resistance, no hassle.  Its unique attributes, including broad-spectrum activity, have earned recommendations from the CDC and cemented its reputation as the top choice for malaria prophylaxis. With a $50–$70 Mln U.S. market for malaria prevention alone, ARAKODA® has already established a foothold in a critical space, showing consistent sales growth.  And let’s not overlook the bigger picture: a global burden of 249 Mln malaria cases annually underscores the dire need for solutions like ARAKODA®.  60 Degrees Pharmaceuticals Positions Tafenoquine to Address Rising Cases of Chronic and Acute Babesiosis Building on its success in malaria, 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) is now tackling babesiosis, a tick-borne disease that is rapidly increasing in the U.S. The company has launched pivotal trials for acute babesiosis and plans to address chronic cases next.  FDA orphan status for tafenoquine highlights its potential as the only game in town for a disease where existing treatments lack efficacy. Babesiosis isn’t just a public health issue—it’s a market with significant potential. With up to 1 Mln chronic cases in the U.S. and growing acute incidence rates, 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) is positioning itself to dominate this emerging space, potentially expanding its patient reach to over 2 Mln. Strong Intellectual Property Portfolio A critical driver of 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP)’s success is its robust and expanding intellectual property portfolio.  The company holds three Orange Book-listed patents for tafenoquine, protecting its malaria prevention innovations until 2035.  With 42 additional patents filed, pending, or optioned across multiple therapeutic areas—including tick-borne diseases and respiratory viruses—60P is playing a long game, ensuring market exclusivity and driving future growth. A Leadership Team That Delivers Behind this powerhouse is a leadership team with unmatched experience and credentials. CEO Geoffrey Dow is a 20-year veteran in tropical disease product development, having spearheaded the regulatory approval of ARAKODA®.  Chief Medical Officer Bryan Smith, with 30+ years of clinical expertise, brings unparalleled insight into pharmacovigilance and regulatory strategy.  And let’s not forget Chief Commercial Officer Kristen Landon, who has launched more than a dozen blockbuster brands, driving revenues well into nine figures. This team isn’t just talking the talk—they’re walking the walk, executing on ambitious plans to scale commercial operations and meet aggressive pro-fit-ability targets by Q4 2026. Evolving Strategies for Commercial Growth 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP)’s commercial strategy for ARAKODA® is razor-sharp: differentiate it from generic competitors with a compelling value story, expand its use among healthcare providers, and reduce access barriers through co-pay assistance programs.  This targeted approach has already shown results, with organic sales growth reflecting increased awareness among prescribers in the Lyme disease community. And it doesn’t stop there.  The company’s forward-looking pipeline includes Celgosivir, targeting dengue and respiratory viruses, and an exploratory program for canine babesiosis, hinting at diversification into veterinary markets. Fiscal Momentum and Milestones Ahead The numbers don’t lie. Recent rounds have injected over $5.9M into 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP)’s coffers, enabling critical funding in commercialization and clinical development.  With three babesiosis trials underway, the company is poised to deliver interim results by early 2026—just in time to accelerate its push toward pro-fit-ability. Upcoming potential catalysts include sales growth milestones, new product development collaborations, and regulatory submissions.  If history is any guide, 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) isn’t just checking boxes; it’s carving out its place in the biotech space. Recent Developments  60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) has partnered with Tufts Medical Center through a groundbreaking Patent License Agreement to accelerate the development and commercialization of tafenoquine for babesiosis treatment and prevention. While tafenoquine is not yet FDA-approved for babesiosis, this agreement represents a significant step toward addressing a growing unmet medical need in combating this serious tick-borne disease. Key highlights of the agreement include: Joint Patent Ownership: Co-ownership of patent applications related to tafenoquine for babesiosis. Exclusive Commercialization Rights: 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) gains exclusive global rights to commercialize tafenoquine for babesiosis. Revenue Sharing: Tufts MC will receive royalties from net sales of tafenoquine-based products labeled for babesiosis. Research Collaboration: Tufts MC retains royalty-free research licenses. Commitment to Development: 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) is dedicated to bringing tafenoquine-based products to market. The Bottom Line 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) is more than a pharma company—it’s a force to be reckoned with in the fight against infectious diseases.  With groundbreaking products, a visionary leadership team, and an aggressive roadmap for growth, (SXTP) is redefining what’s possible in this space.  For those watching closely, one thing is clear: this company doesn’t just participate—it dominates. 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) is drawing attention with several potential catalysts that could help drive its momentum.  With a razor-thin float of only 1.5M shares, the company is positioned for potential market movements.  Recent insider purchases by the CEO reflect confidence in its direction, while a 165% upside target points to notable growth potential. The company has also seen approximately 84% movement over the past six weeks, an indicator of growing market interest.  As of midday, yesterday, January 7, 2025, (SXTP) was triggering 15 Bullish Signals, including the Momentum Indicator, on TradingView’s technical analysis tool using 15 minute time-frames.  Coupled with a robust intellectual property portfolio of over 40 patents, the company is positioning itself to advance its efforts in addressing unmet medical needs.  These elements create a compelling case for keeping an eye on this emerging biotech player. 7 Reasons Why 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP)  is #1 On Our Watchlist… 1. Bullish Signals: Triggering 16 bullish indicators on TradingView’s technical analysis tool, pointing to strong upward momentum. 2. Insider Coverage: CEO insider purchases demonstrate a strong belief in the company’s future and commitment to growth. 3. Analyst Projection: A $3.40 target suggests a potential 165% upside from its recent opening level. 4. Limited Float: With only 1.5M shares available, the stage is set for significant market swings if demand shifts. 5. Growing Recognition: An approximate 84% change in six weeks showcases rising awareness and interest in the market. 6. Robust IP Portfolio: Over 40 patents, including three Orange Book-listed patents, ensure innovation is well-protected and market exclusivity remains strong. 7. FDA-Approved Innovation: ARAKODA® has secured FDA approval and is now targeting the $50–$70M U.S. malaria market, with global implications. Consider Adding 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) to Your Radar This Week… 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) appears to be positioning itself as a standout in the biotech space, combining technical momentum, market potential, and innovation. With 15 Bullish Signals on TradingView’s analysis tool and recent CEO insider buying reinforcing leadership’s confidence, the company is attracting attention. An analyst's target suggesting a 165% potential upside and a limited float of just 1.5M shares set the stage for potential swings as interest continues to grow. The company’s approximate 84% change in six weeks highlights increasing recognition, while its robust intellectual property portfolio and FDA-approved ARAKODA® solidify its position in both the U.S. malaria market and on the global health stage. With these catalysts aligning, 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) is building a compelling narrative for those closely watching the biotech sector. Here’s the deal: (SXTP) has an ultra-tight float of just 1.5M shares, and an analyst is eyeing a target that screams 165% potential upside. If you’re not already digging into (SXTP), now’s the time to consider taking a look.  As of midday yesterday, January 7, 2025, (SXTP) has been lighting up TradingView with 15 Bullish Signals, including the Momentum Indicator. 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) is at the top of our watchlist right now. When we covered (SXTP) the last time it moved approximately 60% in under 24 hours.  All eyes needed on (SXTP) today. Keep a look out for my next update. I’ll check back in with you shortly. Sincerely, Alex Ramsay Co-Founder / Managing Editor Krypton Street Newsletter KryptonStreet.com (“KryptonStreet” or “KS” ) is owned by Media 1717 LLC, a single member limited liability company. Data is provided from third-party sources and KryptonStreet is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile KS brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owner of Media 1717 LLC owns and operates kryptonstreet . com (“KS”). From time to time, KS will publicly disseminate information about a company via website, email, SMS and other points of media. Please see important disclosure information here: kryptonstreet.com/disclaimer/ *Pursuant to an agreement between Media 1717 LLC and TD Media LLC, Media 1717 LLC has been hired by TD Media LLC for a period beginning on 01/07/2025 and ending on 01/10/2025 to publicly disseminate information about (SXTP:US) via digital communications. Under this agreement, Media 1717 LLC has been paid seven thousand five hundred USD (“Funds”) to disseminate information about (SXTP:US) via digital communications. To date, including under the previously described agreement, Meda 1717 LLC has been paid seventeen thousand five hundred USD (“Funds”). These Funds were part of the funds that TD Media LLC received from 60 Degrees Pharmaceuticals Inc., the issuer of (SXTP:US). Neither Media 1717 LLC, TD Media LLC and their member own shares of (SXTP:US). Please see important disclosure information here: https://kryptonstreet.com/disclosure/sxtp/

Media 1717 LLC | 6586 W Atlantic Ave Unit #2086 | Delray Beach, FL 33446 US Unsubscribe | Update Profile | Constant Contact Data Notice